Identification and Analysis of Causal Variants Follow Up on Genome Wide Association Studies for Arthritis and Musculoskeletal and Skin Diseases (R21) | Apply Online

Frequently Asked Questions (FAQs) - NIH NIAMS PAR-12-230 (R21)

1) What is PAR-12-230 trying to accomplish?

This funding opportunity from the NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is designed to move genome-wide association study (GWAS) findings beyond statistical discovery and into practical biology. The goal is to identify the causal gene(s) and causal variant(s) within GWAS-implicated regions relevant to NIAMS mission diseases, and then test how those variants function and contribute to disease mechanisms. Long-term, the intent is to generate biological insight that can inform prediction, diagnosis, and therapy.

2) What problem is this FOA specifically trying to solve?

Many GWAS results highlight broad genomic regions rather than a single clear gene or mutation. That creates a gap between association signals and understanding what genomic change actually drives disease risk. This FOA targets that gap by supporting studies that pinpoint causal variants/genes and explain what they do in relevant cells or tissues.

3) What diseases or research areas are considered in-scope?

The scientific scope is focused on complex diseases affecting arthritis, musculoskeletal conditions, and skin diseases, consistent with the NIAMS mission area (CFDA 93.846: Arthritis, Musculoskeletal and Skin Diseases Research).

4) What is the grant mechanism, and what does that imply about project type?

This is an NIH R21 mechanism (exploratory/developmental). That means projects are expected to be early-stage, innovative, and potentially higher-risk, while still being capable of delivering compelling proof-of-concept results.

5) What kinds of projects are encouraged?

Projects that start with a GWAS-implicated region (or another strongly justified locus) and then efficiently narrow to likely causal variant(s) and gene(s), followed by functional testing to show how those variants affect biology in a way that plausibly contributes to disease.

6) Does the FOA only allow GWAS hits as a starting point?

No. While GWAS-identified regions are the main starting point, applicants may also justify targets using other supporting evidence such as fine-mapping results, sequencing data, functional genomic annotations, eQTL signals, epigenomic marks, chromatin interaction data, or other human genetic/biological data that strengthens the case for a specific locus.

7) What is meant by “moving GWAS findings past the discovery stage”?

It means going beyond reporting that a region is associated with disease. The FOA emphasizes identifying what within that region is causal (specific variant(s) and gene(s)) and producing functional evidence showing what the variant does and how it perturbs relevant molecular pathways.

8) Is the FOA focused on finding more associations?

No. The intent is to accelerate identification of truly causal variants rather than simply reporting additional associations.

9) What types of genetic variants can be studied under this FOA?

Both coding and non-coding variants are within scope. Coding variants may alter protein sequence, while non-coding variants may affect regulatory elements such as enhancers, promoters, transcription factor binding sites, splicing, or non-coding RNAs.

10) What approaches are considered responsive based on the description provided?

Approaches described as fitting well include deep sequencing or dense genotyping of associated loci to capture candidate variants, statistical and experimental fine-mapping to narrow candidates, and functional testing that links specific variants to changes in gene regulation or protein function.

11) What does “functional testing” mean in this context?

Based on the FOA description, functional testing refers to experiments that connect a specific variant (or small set of variants) to a measurable biological effect in relevant cells or tissues, and then link that effect to plausible disease mechanisms and perturbed molecular pathways.

12) Does an application need to identify a single variant right away?

The strongest applications are described as making a clear argument for why a particular variant (or small set of variants) is likely causal and then proposing an efficient strategy to demonstrate a functional effect and plausible disease mechanism. The FOA recognizes that GWAS regions can be broad, so narrowing is part of the work, but the emphasis is on getting to causal variant(s), not staying at the regional association level.

13) What is the funding category and program identifier?

This opportunity is under the NIH discretionary grant category and the health funding activity area, with CFDA program number 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research).

14) What is the maximum award amount mentioned?

The award ceiling listed is $200,000, indicating the maximum amount of funding expected under this announcement for a given award within the stated program limits.

15) Is cost-sharing or matching required?

No. The FOA explicitly states there is no cost-sharing or matching requirement, so applicants are not required to commit non-federal funds to receive the award.

16) Who is eligible to apply?

Eligibility is broad. Eligible applicants include many types of domestic U.S. organizations and also foreign institutions. Listed categories include various government entities (state, county, city/township, special districts), public and private institutions of higher education, independent school districts, nonprofits (with and without 501(c)(3) status, with some categories noted as “other than institutions of higher education”), for-profit organizations (including small businesses), public housing authorities/Indian housing authorities, federally recognized Native American tribal governments, tribal organizations, and other organization types such as faith-based/community-based organizations, regional organizations, and U.S. territories or possessions, including designated serving institutions (e.g., HBCUs, HSIs, TCCUs, Alaska Native/Native Hawaiian Serving Institutions).

17) Are non-U.S. (foreign) institutions eligible?

Yes. Non-U.S. entities (foreign institutions) are eligible to apply based on the eligibility information provided.

18) Are non-U.S. components of U.S. organizations allowed?

Yes. The FOA notes that non-U.S. components of U.S. organizations are eligible, and that foreign components are allowed as defined by NIH policy.

19) Who is the sponsoring agency and issuing institute?

The sponsoring agency is the National Institutes of Health (NIH), and the issuing institute is the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).

20) When was this opportunity posted, and what are the key dates listed?

The opportunity was posted on July 10, 2012, with a later record creation date of July 25, 2013. The original closing date listed was November 20, 2013. The current closing date listed is February 20, 2014, and the archive date is March 20, 2014.

21) Where were applicants directed to find the full announcement?

Applicants were directed to the full announcement on the NIH Grants Guide site.

22) Who was listed for technical access issues?

NIH Office of Extramural Research (OER) webmaster contacts were provided for technical access issues.

23) What is the overall “translation step” this FOA emphasizes?

It emphasizes translating human genetics signals from “this region is associated with disease” to “this specific variant in this gene or regulatory element changes a biological function in relevant cells, and that change plausibly affects disease risk.” The FOA describes this translation as a bottleneck and positions the R21 as a way to encourage creative, fast-moving proof-of-concept studies that can enable larger efforts later.